Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label Trial Investigating the Efficacy and Safety of Continued Treatment With Tisotumab Vedotin in Patients With Solid Tumors Known to Express Tissue Factor.

NCT03245736 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT03245736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03245736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label Trial Investigating the Efficacy and Safety of Continued Treatment With Tisotumab Vedotin in Patients With Solid Tumors Known to Express Tissue Factor.
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 23, 2017
Completion date
January 10, 2019
Enrollment
5 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cervix cancer, endometrium cancer, esophagus cancer, lung cancer, nonsmall cell, ovary cancer, prostate cancer, squamous cell carcinoma of the head and neck